Abstract A05: Improving outcome in homologous recombination competent epithelial ovarian cancer: Hyperthemia and surgeon's perspective

Conclusions: Personalized surgical and chemotherapeutic strategies may be developed for HR stratified EOCs. Primary surgery may be the preferred approach in HRC due to poor chemoresponse and resources should be optimized to achieve complete cytoreduction anticipating difficult resection. Intra-operative hyperthermic treatment and selective HR inhibitors (HSP90) may improve subsequent chemoresponse in HRC. Pre-clinical studies on patient tissues and after HIPEC procedures are proposed in ongoing studies to consolidate our hypothesis.1. Epithelial ovarian cancer: HR assay to stratify as HRD and HRC2. HRC: Primary surgery+ HIPECAdjuvant selective HR inhibitors based on expression of HR proteins/ interaction with other pathways + platinum/ PARPiBenefit: Survival, improved chemoresponse. Also quality of life and time by averting inappropriate use of NACT in poor chemo-responders3. HRD: NACT or primary surgery, role for PARPi in either settingIn select cases with good chemoresponse to NACT, may consider limited surgery or delayed surgery at recurrence ±HIPEC; assess HR status again and targeted chemotherapyBenefit- Quality of life, limited extent of surgery/ delayed surgery without compromising survival as expected to be good chemo-respondersReferences:1. Mukhopadhyay A, et al. Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum and survival. Cancer Research 2012;72: 5675Citation Format: Asim...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Homologous Recombination Defects: Poster Presentations - Proffered Abstracts Source Type: research